AUS_001 / Australis Pharma - LARVOL DELTA

Adaptive transcriptional and immunomodulatory responses to the novel microtubule destabilizer AUS_001 in pancreatic and colorectal cancer models (ESMO 2026) - No abstract available

Immunomodulating • Preclinical • Colorectal Cancer • Oncology • Solid Tumor

Pilot study to investigate optimal dose of microtubule-destabilizing agent AUS001 in mice bearing diffuse midline glioma allograft tumors (SNO 2026) - No abstract available

Preclinical • Brain Cancer • Diffuse Midline Glioma • Glioma • Oncology • Solid Tumor

The novel microtubule-destabilizing compound AUS_001 maintains unique binding to the colchicine site of tubulin and elicits reversible cellular effects relative to other anti-tubulin agents (AACR 2024) - "Comparison of the tubulin-AUS_001 complex structure with the ones of tubulin-colchicine and tubulin-plinabulin revealed that AUS_001 elicits different rearrangements in the T7 loop of β-tubulin versus colchicine and occupies a different zone of the pocket relative to plinabulin, further elaborating its unique binding properties...Conversely, colchicine, CA-4 or paclitaxel administered at the same doses as those applied for AUS_001 failed to reverse the drug-induced phenotypes upon removal resulting in sustained cytotoxicity. In conclusion, we fully characterized the unique binding mode of AUS_001 to the colchicine site of tubulin and elucidated the reversible nature of the target engagement. AUS_001 features a distinctive and reversible molecular interaction with tubulin which provides a plausible explanation for its favorable safety profile compared to other microtubule targeting agents."

Brain Cancer • CNS Tumor • Gastrointestinal Cancer • Glioma • Oncology • Pancreatic Cancer • Solid Tumor

A novel microtubule disruptor exerts broad anticancer efficacy with a tolerable safety profile (AACR 2024) - "Our studies have elaborated the mechanism of AUS_001 as an inhibitor of tubulin polymerization. The favorable safety profile of AUS_001, along with its ability to circumvent Pgp-mediated multidrug resistance, provides potential for efficacy against multiple cancers where microtubule destabilization is proven to be an effective target."

Clinical • Breast Cancer • Hematological Malignancies • Leukemia • Oncology • Solid Tumor

Implication of the novel microtubule targeting agent, AUS_001, in pancreatic cancer cellular signaling. (ASCO-GI 2025) - "Collectively, our findings provide critical insights into the molecular events triggered by AUS_001 in PanCa cells and serve as supporting data for future exploration of AUS_001 as a novel PanCa therapeutic agent."

Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • JUN

The microtubule-destabilizing agent AUS_001 acts as an immunogenic cell death inhibitor (SITC 2024) - "Conclusions The detection of cell surface- and extracellular- appearing DAMPs, as well as surrogate markers of immune cells' activation suggest that AUS_001 induces ICD at cytotoxic concentrations in vitro. Follow up investigations are directed towards defining the role of AUS_001 on the tumor-driven infiltration of immune cells and enhancement of antitumor immunity in the in vivo setting."

Immunogenic cell death • Brain Cancer • CNS Tumor • Glioma • Oncology • Pancreatic Cancer • Solid Tumor • CALR • CXCL10 • HMGB1 • IL1B • IL2 • IL6

The microtubule-destabilizing agent AUS_001 as a candidate for glioblastoma therapy. (ASCO 2024) - "Differences in drug response were investigated between a Temozolomide (TMZ)-resistant human GBM cell line and parental cells. Collectively, we show that AUS_001 has the potential to circumvent significant limitations of clinically approved MTAs, including brain penetration, drug resistance and peripheral neuropathy, making it a promising approach for the treatment of GBM."

Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Pain • Solid Tumor